Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-targeted dendritic cell vaccine as adjuvant immunotherapy for pediatric high-grade glioma and diffuse intrinsic pontine glioma
2024-515295-12-00Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Oct 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of WT1 LAMP mRNA dendritic cell vaccine in glioma and diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by Antwerp University Hospital. Primary endpoints: Feasibility and Safety. Started Oct 2021; status: completed.
02
Drugs
WT1 LAMP mRNA dendritic cell vaccine
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on 2024-515295-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515295-12-00.